Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.

The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.

The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.

The test is designed to identify various obesity phenotypes that doctors can use to personalize treatment plans.

The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.

Academic researchers' efforts to advance CAR T-cell immunotherapy research in this partnership recently received a boost from PICI.

The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.

GE HealthCare will equip a new Theranostics Center of Excellence in Germany with advanced PET/CT imaging and artificial intelligence technologies.

The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.